SV

Street Verdict

Analyst Scorecard

SAILIFE · NSE

Sai Life Sciences Limited

₹1,800.7

+0.69% (+₹12.3)

Prev. close

₹1,788.4

Volume

6,17,754

Delivery %

35.2%

As of

20 Nov 2026

Price history

₹1,800.7+₹360.6 (+25.04%) · 3M
18 Aug 2026 → 20 Nov 2026
1,4001,5001,6001,7001,8001,90018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

Analysts lean bullish

1 analyst stance · last 90 days · one per analyst

Trackable

1 · 1 bull / 0 neutral / 0 bear

Long-Horizon

none in range

Commentary

none in range

Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded

Bullish 100% (1)Neutral 0% (0)Bearish 0% (0)
Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions
Market commentary · 1 · levels, conditionals, previews, macro & hedged views — context, not graded
CallAnalystInstrumentVerdictActions

Fundamentals

About Sai Life Sciences Limited

Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It offers medicinal chemistry, pharmacokinetics, clinical and commercial manufacturing, and process development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was incorporated in 1999 and is headquartered in Hyderabad, India.

Details

Sector

Healthcare

Industry

Diagnostics & Research

CEO

Mr. Krishnam Raju Kanumuri

Headquarters

Hyderabad

Employees

5,224

Key stats

Market cap

₹32,850.41 Cr

P/E ratio (TTM)

91.3

Dividend yield

0.00%

EPS (TTM)

₹16.93

Beta (1Y · daily vs NIFTY 50)

0.72

Shares float

13.33 Cr

EPS · quarter ended Jun 2026

₹3.42

Financial Performance

01 · Financials

0 Cr1000 Cr2000 Cr3000 Cr₹0%5%10%15%20%FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

05101520₹FY23FY24FY25FY26

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based · pre-FY23 not filed in verifiable form

-40%-20%0%20%40%FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

Pre-FY23 not filed in verifiable form

0 Cr1000 Cr2000 Cr3000 Cr4000 Cr₹0×0.5×1×1.5×FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

Pre-FY23 not filed in verifiable form

0 Cr1000 Cr2000 Cr3000 Cr4000 Cr₹FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

Pre-FY23 not filed in verifiable form

-500 Cr0 Cr500 Cr1000 Cr₹FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY23FY24FY25FY26
₹1,196.95 Cr₹1,456.47 Cr₹1,660.39 Cr₹2,153.23 Cr
EBITDA
₹192.90 Cr₹314.58 Cr₹442.44 Cr₹672.29 Cr
₹9.99 Cr₹82.81 Cr₹170.13 Cr₹348.91 Cr
Diluted EPS
₹0.48₹3.98₹8.61₹16.08

Total expenses (as filed), Employee benefit expense, Other expenses, Other income have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Net income for Mar 2026 could not be checked against the company's own annual report: this page shows ₹348.91 Cr while the annual report gives ₹341.48 Cr (2.1% apart).

EBITDA for Mar 2026 could not be checked against the company's own annual report: this page shows ₹672.29 Cr while the annual report gives ₹641.09 Cr (4.6% apart).

09 · Balance Sheet

Annual

Line itemFY23FY24FY25FY26
₹2,186.65 Cr₹2,275.14 Cr₹3,159.98 Cr₹3,626.14 Cr
₹932.38 Cr₹927.66 Cr₹352.38 Cr₹288.45 Cr
Stockholders' equity
₹888.09 Cr₹975.14 Cr₹2,128.36 Cr₹2,483.69 Cr

CWIP, Others have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY23FY24FY25FY26
₹219.40 Cr₹263.09 Cr₹314.05 Cr₹509.13 Cr
Investing cash flow
₹-101.78 Cr₹-192.38 Cr₹-536.67 Cr₹-395.41 Cr
₹-200.65 Cr₹-95.30 Cr₹301.43 Cr₹-123.68 Cr
Capital expenditure
₹-113.08 Cr₹-181.69 Cr₹-369.28 Cr₹-592.96 Cr
End cash position
₹35.53 Cr₹11.97 Cr₹91.05 Cr₹81.91 Cr

Dividends paid has filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemDec 24–Dec 24(2Q)Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Promoter35.24%35.17%35.15%34.94%34.70%34.61%34.53%
Public64.76%64.83%64.85%65.06%65.30%65.39%65.47%
Employee trusts0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Sai Life Sciences Limited₹32,875.91 Cr₹1,558.291.413.2414.0%0.12+28.7%+68.9%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

SAILIFE

Sai Life Sciences rises 2.11% in Wednesday's session

Global Banking & Finance Review · 4 days ago

SAILIFE

Aragen Life Sciences Plans ₹1,500 Crore Expansion Investment

Voice of Healthcare · 4 days ago